Preventing the Respiratory Failure Causing COVID-19 Mortality, Potent New Drugs Targeting Hyperinflammation
This project will develop highly potent novel drugs to prevent and cure acute respiratory distress syndrome, the rapid-onset life-threatening respiratory failure killing patients with COVID-19 and other respiratory viruses. Our drugs will save lives by targeting adipokine receptors responsible for the extreme overreaction of the body’s immune system and hyperactive inflammatory response that underpin rapid patient decline from respiratory failure.
Investigators
Dr Lisa Philp | APCRC-Q, IHBI, QUT, TRI |
Duration
2020 - 2022
Funding
Advance Queensland - Industry Research Fellowship - Mid Career | $150,000 |
Industry partner and QUT contributions | $150,000 |
Project funding total | $300,000 |